The Question Behind the Search
If you searched "what is a microdose of tirzepatide" or "what is considered a microdose of tirzepatide," you are looking for a number. Specifically, the weekly dose that actually counts as a microdose, how that compares to standard Mounjaro and Zepbound dosing, and whether the smaller dose makes sense for your situation. This article gives you the number, the honest tradeoffs, and a clear view of who benefits from microdose tirzepatide and who does not.
Educational content. Not medical advice. A licensed-provider evaluation determines what is appropriate for any individual patient.
The Short Answer
A microdose of tirzepatide is generally any weekly dose below the FDA-approved starter dose of 2.5 mg. In practice, compounded microdose tirzepatide protocols typically fall in the range of 0.50 mg to 1.50 mg per week, with some patients beginning as low as 0.25 mg. The standard tirzepatide protocol used in Mounjaro and Zepbound starts at 2.5 mg weekly and titrates up through a maintenance range of 5 mg to 15 mg weekly. A microdose sits well below the starter dose and often stays there.
The term "microdose" is not defined by the FDA. It is a clinical convention that emerged from compounding pharmacy practice and from providers who wanted a gentler entry point for sensitive patients or a maintenance option for patients who had already reached their weight-loss goals. The same convention applies to semaglutide microdose protocols, which we cover in our piece on what is a microdose of semaglutide.
Standard Dose vs Microdose Side by Side
| Standard tirzepatide (Zepbound) | Microdose tirzepatide | |
|---|---|---|
| Starting dose | 2.5 mg/week | 0.50 to 1.00 mg/week (commonly) |
| Typical maintenance | 5 to 15 mg/week | 1.00 to 2.00 mg/week |
| Titration interval | Every 4 weeks | Slower, provider-guided (often 2 to 4 weeks) |
| Average weight loss (6 months) | ~15 to 20 percent of body weight | ~4 to 9 percent of body weight |
| Side-effect intensity | Moderate; nausea and GI effects common during titration | Generally milder |
| Madison Meds compounded pricing | From $249 first month, $349 ongoing | From $149 first month, $199 ongoing |
The weight-loss figures are approximate. Standard-dose numbers reflect the SURMOUNT-1 trial average for adults with obesity at 72 weeks on tirzepatide 5 mg, 10 mg, or 15 mg. Microdose figures are based on clinical observation and aggregated reports from compounded GLP-1 practices; randomized trial data specific to microdose tirzepatide protocols are limited, and outcomes are individual.
Why Microdose Tirzepatide at All?
Microdose tirzepatide is a genuine clinical option, not a marketing gimmick, and the underlying mechanism has been studied in research for dose-response across the GLP-1 and GIP receptor systems. There are five common reasons a licensed provider might consider a microdose protocol for an eligible patient.
- Side effect sensitivity. Tirzepatide is potent. Patients on standard starter doses frequently report nausea, reflux, constipation, or fatigue during the first weeks. A microdose entry point can preserve the appetite-regulation benefit while reducing the intensity of GI effects during titration.
- Modest weight-loss goals. A patient with a 10 to 25 pound goal is not in the same population as a patient targeting 75 pounds. Microdose protocols are often well-matched to smaller goals where the full standard dose would be unnecessary.
- Maintenance after weight loss. Patients who reached their goal on standard-dose therapy and want to maintain rather than continue losing sometimes step down to a microdose. This is one of the fastest growing use cases, including for patients exiting standard tirzepatide who want to soften the rebound risk we cover in our article on weight regain after stopping semaglutide and tirzepatide.
- Metabolic and appetite-regulation support. Some patients use low-dose tirzepatide not primarily for weight loss but for glucose control, reduction of "food noise," or insulin sensitivity support in coordination with their broader plan.
- Cost considerations. Lower dose means lower active ingredient cost per month. Microdose compounded tirzepatide is the more accessible price tier for patients who want the dual GLP-1 and GIP mechanism without the full standard-dose monthly cost.
What a Microdose Does Not Do
Honesty matters here, because the marketing around microdosing has at times outrun the evidence.
- It is not a shortcut to standard-dose results. If a patient's goal requires the average outcome of standard-dose tirzepatide therapy, a microdose is unlikely to deliver that. Dose response is real and meaningful with tirzepatide in particular.
- It is not "safer" simply because it is smaller. The same contraindications apply. Personal or family history of medullary thyroid carcinoma, MEN 2, pancreatitis, severe GI disease, gallbladder issues, and certain other conditions remain relevant regardless of dose.
- It is not a research-grade protocol you can self-manage. Compounded tirzepatide is a prescription product. The microdose protocol is set, monitored, and adjusted through a licensed-provider evaluation, not picked from a chart on the internet.
- It is not the same as Mounjaro or Zepbound. Compounded tirzepatide is not an FDA-approved finished drug product. It is dispensed by a US-licensed compounding pharmacy under specific federal and state pharmacy regulations.
How a Microdose Protocol Is Set
A typical microdose tirzepatide protocol through Madison Meds works like this. A patient completes the intake and shares full medical history. An independent licensed provider in the Madison Meds network reviews the file, conducts a telehealth evaluation, and decides whether the patient is an appropriate candidate for compounded tirzepatide. If yes, the provider sets the starting dose, the titration plan, and the follow-up schedule. The medication is dispensed by a US-licensed compounding pharmacy and shipped to the patient. Most starter protocols begin at 0.50 mg or 1.00 mg weekly and are adjusted over the first 8 to 12 weeks based on response and tolerability.
This is different from buying research-grade peptide vials online without a prescription. See our piece on prescribed peptides versus research peptides for the full distinction.
Microdose Tirzepatide vs Microdose Semaglutide
Patients often ask which is "better" at the microdose tier. There is no universal answer, but there are clear patterns. Tirzepatide acts on both GLP-1 and GIP receptors, which produces stronger average appetite and weight effects at comparable doses; semaglutide acts on GLP-1 alone. In practical terms, a 1.00 mg weekly microdose of tirzepatide tends to feel "stronger" than a 0.10 mg weekly microdose of semaglutide. Some patients tolerate one significantly better than the other.
The full mechanism comparison is in our tirzepatide versus semaglutide comparison. The right choice is set during the licensed-provider evaluation.
What to Expect in the First 90 Days on a Microdose
Patient experiences vary, but here is the general arc most patients describe.
- Weeks 1 to 2. Mild reduction in appetite. Many patients notice less "food noise" within the first week. GI side effects are typically minimal at microdose tirzepatide levels.
- Weeks 3 to 6. Weight loss begins gradually, typically 0.75 to 2.0 pounds per week depending on starting weight and dose. Provider check-in determines whether to hold, increase, or adjust.
- Weeks 7 to 12. A clearer pattern emerges. Patients on a working microdose typically see continued steady loss without significant side effects. Patients who are not responding may have their dose carefully adjusted by the provider.
Outcomes are individual. Some patients respond strongly to small doses; others need a higher dose to see meaningful change. The follow-up structure is what keeps the protocol matched to the patient.
Compounded Microdose Tirzepatide Through Madison Meds
Through Madison Meds, compounded tirzepatide microdose is available to eligible adults after a licensed-provider evaluation, with the medication dispensed by a US-licensed compounding pharmacy. The first-month price for the microdose program is $149, and ongoing monthly pricing is $199. The standard-dose compounded tirzepatide program is $249 first month and $349 ongoing. New-patient promo codes vary and may apply through the site popup.
Both programs include the licensed-provider visit, medication, supplies, and discreet home shipping. The protocol is adjusted by your assigned licensed provider through ongoing follow-up visits.
Curious if a microdose of tirzepatide is right for you?
An independent licensed provider in the Madison Meds network will review your goals and medical history and recommend the right protocol. Compounded tirzepatide microdose starts at $149 your first month.
See Microdose TirzepatideFrequently Asked Questions
What is considered a microdose of tirzepatide?
A microdose of tirzepatide generally refers to a weekly dose below the FDA-approved starter dose of 2.5 mg used in Mounjaro and Zepbound. Compounded microdose protocols commonly run in the 0.50 mg to 1.50 mg per week range, with some providers starting as low as 0.25 mg. The exact dose is set by a licensed provider based on the patient's goals, history, and response.
What is a typical microdose of tirzepatide?
A typical microdose of tirzepatide is 1.0 mg weekly, which is studied in research as a tolerable entry point well below the 2.5 mg starter and substantially below the 5 mg to 15 mg maintenance range. Some protocols begin at 0.50 mg weekly and titrate upward by 0.50 mg increments every two to four weeks under licensed-provider supervision.
How much is a microdose of tirzepatide?
Madison Meds compounded tirzepatide microdose starts at $149 per month for new patients and is $199 per month ongoing. Pricing includes the licensed-provider evaluation, the compounded medication dispensed by a US-licensed compounding pharmacy, supplies, and discreet home shipping.
How much weight loss can you expect on a microdose of tirzepatide?
Microdose tirzepatide produces slower and typically smaller average weight loss than full-dose protocols. Many patients report 4 to 9 percent of body weight over six months, compared with the 15 to 20 percent average seen in standard-dose tirzepatide trials. Individual results vary and outcomes are individual.
Is microdose tirzepatide better than microdose semaglutide?
Neither is universally better. Tirzepatide acts on both GLP-1 and GIP receptors, which can deliver stronger appetite and weight effects at comparable doses; semaglutide is GLP-1 only. Some patients tolerate semaglutide better at microdose levels. The right protocol depends on history, response, and goals, and is set during the licensed-provider evaluation.
Compounded medications are not FDA-approved finished drug products. This article is Educational content and is Not medical advice. Compounded tirzepatide is available through Madison Meds after a licensed-provider evaluation, with the medication dispensed by a US-licensed compounding pharmacy. A licensed provider will review your full medical history before any prescription, and not all patients are appropriate candidates for GLP-1 therapy. The dose ranges, weight-loss figures, and timelines discussed are general references; individual results vary and outcomes are individual.